After 5 Years, Rivals Emerge Ready to Give Viagra a Fight

Article Abstract:

Pfizer's Viagra, the drug to treat erectile dysfunction, will soon face competition from Levitra, made by GlaxoSmithKline and Bayer, and Eli Lilly's Cialis, currently under final F.D.A. review. Levitra will be marketed as faster-acting than Viagra, while Cialis will be touted as effective for 36 hours as compared to 4 to 5 hours for its rivals. Industry experts predict that Cialis has a better chance than Levitra of taking away some of Viagra's dominant market share in the U.S., as Cialis already outsells Levitra abroad, although Viagra still leads in market share overseas.

Germany, Forecasts, trends, outlooks, Market share, Forecasts and trends, Drug therapy, Market trend/market analysis, Eli Lilly and Co., Pfizer Inc., Impotence, Chemical industry, LLY, PFE, Viagra (Medication), Company market share, GlaxoSmithKline Inc., Cialis (Medication), Levitra (Medication)

---

Study Links a Fourth Painkiller To an Increase in Heart Problems

Article Abstract:

A study sponsored by the National Institutes of Health, indicates that Aleve, an over-the-counter painkiller from Bayer AG, may increase the risk of heart attack. Officials are asking that consumers not exceed the recommended dosage.

Science & research, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Research, Causes of, Complications and side effects, Heart attack, Nonsteroidal anti-inflammatory drugs, Nonsteroidal anti-inflammatory agents, Dosage and administration, Analgesics, Aleve (Medication)

---

Drug Makers Seek to Mend Their Fractured Image

Article Abstract:

The pharmaceutical industry has begun to provide discount drugs to the poor, but its public image remains tarnished. As drug prices continue to rise, Congress is being pressured to legalize drug imports or consider price controls.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Administration of General Economic Programs, Pharmaceutical Preparation Manufacturing, Commodity & service prices, Public affairs, Drugs, Imports, Pharmaceutical Preparations, Metabolic Agents NEC, Metabolic Agents, Import Regulations, Interpretation and construction, Prices and rates, Public opinion polls, Public opinion, Public relations, Company public relations, Company pricing policy

Similar abstracts:

• Abstracts: 'It was the right decision, it was a just cause and it liberated the people'
• Abstracts: Pet Valu seeks to mark its territory. Women losing out on top jobs in capital markets industry
• Abstracts: Music giant chops prices to combat downloads. Sobeys sees bigger picture in Cineplex deal. Technology makes sharing music easy
• Abstracts: Ottawa looks to boost foreign investment. Construction projects hit record high. Potash looks to Dead Sea for growth

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.